N-allyl-N-methyl-tryptamine | 1366416-29-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N-allyl-N-methyl-tryptamine
• 英文别名: N-methyl-N-allyltryptamine；N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine
• CAS: 1366416-29-6
• 化学式: C₁₄H₁₈N₂
• 分子量: 214.31
• InChiKey: GXCLVBGFBYZDAG-UHFFFAOYSA-N

物化性质

• 沸点：
  360.5±30.0 °C(Predicted)
• 密度：
  1.055±0.06 g/cm3(Predicted)
• 溶解度：
  乙腈：25.0（最大浓度 mg/mL）；116.65（最大浓度 mM）

计算性质

• 辛醇/水分配系数(LogP)：
  2.83
• 重原子数：
  16.0
• 可旋转键数：
  5.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  19.03
• 氢给体数：
  1.0
• 氢受体数：
  1.0

反应信息

• 作为反应物：
  描述：

  N-allyl-N-methyl-tryptamine 在 Wilkinson's catalyst 作用下， 以 甲苯 为溶剂， 反应 5.0h， 生成 1-Ethyl-2-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole
  参考文献：
  名称：

  通过N-烯丙基丙胺的异构化合成四氢β-咔啉：以Pictet-Spengler为主题的金属催化变体。

  摘要：

  提出了一种有效且广泛适用的四氢-β-咔啉的经典Pictet-Spengler合成方法。该方法依赖于烯丙基胺的金属催化异构化以形成反应性亚胺中间体，该中间体可以被束缚的吲哚亲核试剂捕获。

  DOI：

  10.1039/c2cc17704h
• 作为产物：
  描述：

  N-甲基烯丙基胺 、 3-(2-溴乙基)吲哚 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 16.0h， 以52%的产率得到N-allyl-N-methyl-tryptamine
  参考文献：
  名称：

  通过N-烯丙基丙胺的异构化合成四氢β-咔啉：以Pictet-Spengler为主题的金属催化变体。

  摘要：

  提出了一种有效且广泛适用的四氢-β-咔啉的经典Pictet-Spengler合成方法。该方法依赖于烯丙基胺的金属催化异构化以形成反应性亚胺中间体，该中间体可以被束缚的吲哚亲核试剂捕获。

  DOI：

  10.1039/c2cc17704h

文献信息

• [EN] ALKYL QUARTERNARY AMMONIUM TRYPTAMINES AND THEIR THERAPEUTIC USES<br/>[FR] TRYPTAMINES D'AMMONIUM QUATERNAIRE D'ALKYLE ET LEURS UTILISATIONS THÉRAPEUTIQUES
  申请人：CAAMTECH LLC

  公开号：WO2021041407A1

  公开（公告）日：2021-03-04

  The invention relates to a compound of formula (I): The invention also relates to crystalline compounds of formula (I). The invention relates to compositions comprising, consisting essentially of, or consisting of a compound of formula (I) and an excipient. The invention also relates to pharmaceutical compositions comprising a therapeutically effective amount of a compound of formula (I) where the excipient is a pharmaceutically acceptable carrier. The invention further relates to therapeutic uses of compounds of formula (I).

  本发明涉及公式(I)的化合物。本发明还涉及公式(I)的晶体化合物。本发明涉及由公式(I)的化合物和辅料组成、基本上由公式(I)的化合物和辅料组成或仅由公式(I)的化合物和辅料组成的组合物。本发明还涉及制药组合物，其中所述的公式(I)的化合物为治疗有效量，所述的辅料为药用可接受载体。本发明进一步涉及公式(I)的化合物的治疗用途。
• ALKYL QUARTERNARY AMMONIUM TRYPTAMINES AND THEIR THERAPEUTIC USES
  申请人：Caamtech, LLC

  公开号：EP4017859A1

  公开（公告）日：2022-06-29
• METHODS OF TREATING MOOD DISORDERS
  申请人：Kruegel Andrew Carry

  公开号：US20220041551A1

  公开（公告）日：2022-02-10

  Methods of treating mood disorders with compounds disclosed herein. Also provided are pharmaceutical compositions that include those compounds.
• TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH
  申请人：STAMETS Paul Edward

  公开号：US20220125809A1

  公开（公告）日：2022-04-28

  Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines or in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum ) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica , or Cannabis ruderalis , optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients.
• [EN] TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH<br/>[FR] COMPOSITIONS DE TRYPTAMINES DESTINÉES À AMÉLIORER L'EXCROISSANCE DES NEURITES
  申请人：STAMETS PAUL EDWARD

  公开号：WO2021101926A1

  公开（公告）日：2021-05-27

  Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines or in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica, or Cannabis ruderalis, optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients.